Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer

Suresh S. Ramalingam, Mikhail Shtivelband, Ross A. Soo, Carlos H. Barrios, Anatoly Makhson, José G.M. Segalla, Kenneth B. Pittman, Petr Kolman, Jose R. Pereira, Gordan Srkalovic, Chandra P. Belani, Rita Axelrod, Taofeek K. Owonikoko, Qin Qin, Jiang Qian, Evelyn M. McKeegan, Viswanath Devanarayan, Mark D. McKee, Justin L. Ricker, Dawn M. CarlsonVera A. Gorbunova

Research output: Contribution to journalArticle

33 Scopus citations

Abstract

Purpose: Linifanib, a potent, selective inhibitor of vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptors, has single-agent activity in non-small-cell lung cancer (NSCLC). We evaluated linifanib with carboplatin and paclitaxel as first-line therapy of advanced nonsquamous NSCLC. Patients and Methods: Patients with stage IIIB/IV nonsquamous NSCLC were randomly assigned to 3-week cycles of carboplatin (area under the curve 6) and paclitaxel (200 mg/m2) with daily placebo (arm A), linifanib 7.5 mg (arm B), or linifanib 12.5 mg (arm C). The primary end point was progression-free surviva (PFS); secondary efficacy end points included overall survival (OS) and objective response rate. Results: One hundred thirty-eight patients were randomly assigned (median age, 61 years; 57% men; 84% smokers). Median PFS times were 5.4 months (95% CI, 4.2 to 5.7 months) in arm A (n = 47), 8.3 months (95% CI, 4.2 to 10.8 months) in arm B (n = 44), and 7.3 months (95% CI, 4.6 to 10.8 months) in arm C (n = 47). Hazard ratios (HRs) for PFS were 0.51 for arm B versus A (P = .022) and 0.64 for arm C versus A (P = .118). Median OS times were 11.3, 11.4, and 13.0 months in arms A, B, and C, respectively. HRs for OS were 1.08 for arm B versus A (P = .779) and 0.88 for arm C versus A (P = .650). Both linifanib doses were associated with increased toxicity, including a higher incidence of adverse events known to be associated with VEGF/PDGF inhibition. Baseline plasma carcinoembryonic antigen/cytokeratin 19 fragments biomarker signature was associated with PFS improvement and a trend toward OS improvement with linifanib 12.5 mg. Conclusion: Addition of linifanib to chemotherapy significantly improved PFS (arm B), with a modest trend for survival benefit (arm C) and increased toxicity reflective of known VEGF/PDGF inhibitory effects.

Original languageEnglish (US)
Pages (from-to)433-442
Number of pages10
JournalJournal of Clinical Oncology
Volume33
Issue number5
DOIs
StatePublished - Feb 10 2015

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer'. Together they form a unique fingerprint.

  • Cite this

    Ramalingam, S. S., Shtivelband, M., Soo, R. A., Barrios, C. H., Makhson, A., Segalla, J. G. M., Pittman, K. B., Kolman, P., Pereira, J. R., Srkalovic, G., Belani, C. P., Axelrod, R., Owonikoko, T. K., Qin, Q., Qian, J., McKeegan, E. M., Devanarayan, V., McKee, M. D., Ricker, J. L., ... Gorbunova, V. A. (2015). Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer. Journal of Clinical Oncology, 33(5), 433-442. https://doi.org/10.1200/JCO.2014.55.7173